In April 2012, the American Academy of Neurology and the American Headache Society issued new guidelines on preventive treatment for episodic migraine. Although the guidelines provide valuable information regarding drug efficacy, they do not address the equally important issue of adverse events.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Low use of placebo in comparative drug rcts in migraine. Are clinical investigators unaware of basic methodological issues?
The Journal of Headache and Pain Open Access 21 February 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lipton, R. B. et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 68, 343–349 (2007).
Silberstein, S. D. et al. Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78, 1337–1345 (2012).
Holland, S. et al. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults. Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78, 1346–1353 (2012).
Evers, S. et al. EFNS guideline on the drug treatment of migraine—revised report of an EFNS task force. Eur. J. Neurol. 16, 968–981 (2009).
Editor's note to authors and readers: levels of evidence coming to Neurology®. Neurology®[online], (2009).
Shaygannejad, V. et al. Comparison of the effect of topiramate and sodium valproate in migraine prevention: a randomized blinded crossover study. Headache 46, 642–648 (2006).
Tfelt-Hansen, P. et al. Guidelines for controlled trials of drugs in migraine: third edition. A guide for investigators. Cephalalgia 32, 6–38 (2012).
Schellenberg, R., Lichtenthal, A., Wöhling, H., Graf, C. & Brixius, K. Nebivolol and metoprolol for treating migraine: an advance on β-blocker treatment? Headache 48, 118–125 (2008).
Linde, K. & Rossnagel, K. Propranolol for migraine prophylaxis. Cochrane Database of Systematic Reviews, Issue 2. Art. No.: CD003225. http://dx.doi.org/10.1002/14651858.CD003225.pub2.
Jackson, J. L. et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 341, c5222 (2010).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Tfelt-Hansen, P., Hougaard, A. New US guidelines for preventive treatment of migraine. Nat Rev Neurol 8, 419–421 (2012). https://doi.org/10.1038/nrneurol.2012.115
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.115
This article is cited by
-
Low use of placebo in comparative drug rcts in migraine. Are clinical investigators unaware of basic methodological issues?
The Journal of Headache and Pain (2013)
-
Outcome of patients with chronic migraine with medication overuse and depression after duloxetine: influence of coexisting obsessive compulsive disorder
Neurological Sciences (2013)
